Viewing nowDioratan Tablet 80 mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

MFDS item code 200807367 · Notified 2008.07.03 · Insurance code 671804280
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is primarily used for patients with essential hypertension and heart failure. It can also be used to treat heart failure patients (NYHA class II to IV) who are intolerant to ACE inhibitors. Moreover, it helps reduce the risk of death in patients with left ventricular failure or dysfunction after myocardial infarction. In summary, this medication is used for managing hypertension, heart failure, and cardiac health after myocardial infarction.
1. Essential hypertension Take with water during or between meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Over the following several weeks, increase the dose according to the patient's tolerability, giving 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is preferable not to exceed 80 mg daily. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1) Children: The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. 6. Children: The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during pregnancy, particularly in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Do not take this medication if allergic reactions occur, or if you have severe liver disease, cirrhosis, bile duct obstruction, severe kidney impairment, primary aldosteronism, or a history of angioedema. Elderly patients, those with hyperkalemia, mild to moderate liver impairment, valvular heart disease or obstructive cardiomyopathy, cardiovascular disease, or those with sodium or fluid depletion should use this medication cautiously and monitor blood pressure and kidney function closely. Blood pressure may drop sharply at the beginning of treatment; if dizziness or fainting occurs, notify medical personnel immediately. Patients undergoing dialysis or those taking diuretics are at increased risk of hypotension. This medication can increase potassium levels; therefore, if taken with potassium supplements or potassium-sparing diuretics, serum potassium levels should be checked frequently. There may be interactions if taken with other antihypertensives, diuretics, non-steroidal anti-inflammatory drugs (NSAIDs), or lithium; consult with healthcare professionals before use. During treatment, abnormalities such as liver dysfunction, kidney function decline, blood pressure drop, increased potassium levels, and angioedema may occur, so report any symptoms to medical personnel immediately. Breastfeeding women should avoid this medication, and the safety of use in children or adolescents under 18 years of age has not been established. In case of overdose, severe hypotension or altered consciousness may occur, requiring immediate medical attention.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent exposure to air and moisture, and keep it in a cool place below 30 degrees Celsius, avoiding direct sunlight and high temperatures.
Pink round film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.